Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308134 | 0.75 | DPP4 (0.43) | DPP4DPP8USP2MAPK1FGFR1 | |
| SCHEMBL6012147 | 0.75 | DPP4 (0.43) | DPP4DPP8USP2MAPK1FGFR1 | |
| SCHEMBL4724897 | 0.75 | DPP4 (0.50) | DPP4KMT2ADPP8FGFR1 | |
| SCHEMBL17940717 | 0.74 | FGFR1 (0.61) | FGFR1 | |
| SCHEMBL24686841 | 0.73 | DPP4 (0.41) | DPP4DPP8GRM5FGFR1 | |
| SCHEMBL21187468 | 0.73 | DPP4 (0.51) | DPP4PSMB8DPP8FGFR1 | |
| SCHEMBL15268278 | 0.73 | DPP4 (0.41) | DPP4DPP8FGFR1 | |
| SCHEMBL1013519 | 0.73 | ALDH1A1 (0.50) | DPP4KMT2ADPP8NSD2FGFR1 | |
| SCHEMBL16140228 | 0.73 | DPP4 (0.43) | DPP4DPP8FGFR1 | |
| SCHEMBL8050564 | 0.73 | FGFR1 (0.56) | DPP4KMT2ADPP8FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118974035-A | 2-Aminoimidazole derivatives as PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019197549-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | CDK1, CDK2, CDK15 | DPP4 1377/4885KMT2A 1633/4885PSMB8 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.